Navigation Links
Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
Date:7/18/2013

NEW YORK, July 18, 2013 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. announces it has signed a definitive licensing agreement with U-Bio Med Inc., a medical technology device company in South Korea, for the worldwide commercialization of the company's microneedle device technology. 

The definitive agreement, signed on July 14, 2013, provides Aquavit Pharmaceuticals a perpetual exclusive right to license, sub-license, improve and/or commercialize the patented microneedle technology and all of its derivatives.  The companies have not disclosed the deal amount.

"Dr. Eum is an exceptional scientist. The technology will accelerate our consorted development towards disruptive innovation in drug delivery," said Sobin Chang, Aquavit's Chief Executive Officer.

Aquavit will own all intellectual property pertaining to further development of Aquavit's pipeline products.  The company has begun the registration process with the FDA and CE for specialized use.

"In addition to the patented delivery mechanism of the needles, we are using pure gold to ensure quality and safety," said Dr. Nyun-Sik Eum, CEO of U-Bio Med.

AQT-001 has been FDA registered and will be commercially available in US and globally shortly.  The technology will address the unmet needs of the 11 billion dollar medical aesthetics market and the 30 billion dollar vitamin and mineral market.

"It is an innovative delivery system for botulinum toxins and dermal fillers.  I use it with Botox, hyaluronic acid-based fillers and vitamin combinations," said Dr. David Shafer, Chief Medical Technology Officer.

About U-Bio Med Inc.

U-Bio Med (Ubiquitous Bio Medical Equipment) is a Korean company that specializes in the development and manufacturing of precise test equipment, bio-sensor based optical systems and practical medical devices.  

About Aquavit Pharmaceuticals, Inc.

Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical device, and health technologies. For more information, visit www.aquavitpharma.com or contact Anne Hargreaves at 212-210-9272.


'/>"/>
SOURCE Aquavit Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
2. Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys
3. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):